Gene Therapy for Allergic Airway Diseases

Maes, Tania; Tournoy, Kurt G.; Joos, Guy

doi:10.1007/s11882-011-0177-8

Cited by 25 publications

(18 citation statements)

References 46 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Environmental factors contribute considerably to the development of allergic diseases, and it is therefore unrealistic to target the "genetic predisposition" of asthma patients via gene therapy. However, future approaches will surely target specific mediators or cells that play an important function in the disease's pathogenesis to provide an alternative therapy for severe, uncontrolled asthma (Maes et al, 2011).…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Construction of a lentiviral vector encoding heme oxygenase 1 and its introduction into mouse adipose tissue-derived stem cells

Zhu

2015

Genet. Mol. Res.

View full text Add to dashboard Cite

ABSTRACT. Many studies exist concerning the use of stem cells as delivery vehicles in gene therapy, expressing genes such as vascular endothelial growth factor 165 and hepatocyte growth factor. However, few reports regarding adipose tissue-derived stem cells (ADSCs) and the heme oxygenase 1 (HO-1) gene have been published. Therefore, we established a lentiviral vector encoding HO-1 and used this to infect ADSCs with the aim of producing therapeutic seed cells. In this study, ADSCs were isolated from mouse adipose tissue (AT), cultured, and identified according to the expression of antigens on their cell surface and their capacity for multilineage differentiation. A lentiviral vector encoding HO-1 was constructed, ADSCs were infected with this, and HO-1 protein expression was examined by western blotting. Our results show that ADSCs can be isolated from mouse AT, while DNA sequencing demonstrated that HO-1 was successfully transferred to the vector fused with GFP. Following 293T cell transfection, lentivirus titers were approximately 3 x 10 8 TU/mL. Fluorescence microscopy confirmed the expression of the HO-1 construct in lentivirus-infected ADSCs and the overexpression of HO-1 protein in these cells was verified by western blot. The production of ADSCs overexpressing HO-1 described in this study may aid in the development of a novel method for the treatment of asthma.

show abstract

Section: Discussionmentioning

confidence: 99%

“…Previously, gene therapy has predominantly focused on those illnesses for which no effective alternative therapies exist, such as cancer and cystic fibrosis. However, recent developments in this field have included work on other diseases, including asthma and allergic rhinitis (Maes et al, 2011).…”

Section: Introductionmentioning

confidence: 99%

Construction of a lentiviral vector encoding heme oxygenase 1 and its introduction into mouse adipose tissue-derived stem cells

Zhu

2015

Genet. Mol. Res.

View full text Add to dashboard Cite

show abstract

“…Gene therapy interventions in asthma are aimed at inhibiting Th2 transcription factors, cytokines and function, or overexpressing Th2 antagonists [116]. Because of the reciprocal regulation of T helper cells, it was anticipated that increasing IFN-γ levels would promote a Th1 response by blocking Th2 cytokine production.…”

Section: Accepted Manuscriptmentioning

confidence: 99%

“…It was found that the antiangiogenesis treatment with VEGF siRNA combined with the chemotherapy by GMP resulted in an additive antitumor effect better than with VEGF siRNA or GMP alone [139]. Finally, among the gene-silencing technique, miRNA recently gained a great deal of interest, also in lung diseases [116]. Decreased expression of certain miRNAs increases the translation of oncogenic genes, while, conversely, overexpression of other miRNAs repress the expression of tumor suppressor genes (often referred to as onco-miRNAs).…”

Section: A C C E P T E D Accepted Manuscriptmentioning

confidence: 99%

Nanocomplexes for gene therapy of respiratory diseases: Targeting and overcoming the mucus barrier

Gioia

Trapani

Castellani

et al. 2015

Pulmonary Pharmacology & Therapeutics

View full text Add to dashboard Cite

“…The potent ability of small interfering RNA (siRNA) to inhibit the expression of complementary RNA transcripts is being exploited as a new approach for treating diseases, including asthma (Maes et al, 2011). siRNA is a short, double-stranded RNA (dsRNA) molecule that can target a specific sequence of mRNA for degradation via a cellular process known as RNA interference (RNAi) (Dorsett and Tuschl, 2004).…”

Section: Introductionmentioning

confidence: 99%

Bottom-up assembly of RNA nanoparticles containing phi29 motor pRNA to silence the asthma STAT5b gene

Qiu¹,

Peng²,

Shi³

et al. 2012

Genet. Mol. Res.

View full text Add to dashboard Cite

ABSTRACT. Activation of the transcription factor signal transducer and activator of transcription 5b (STAT5b) is a key event in the development of asthma. The potent ability of small interfering RNA (siRNA) to inhibit the expression of STAT5b mRNA has provided a new class of therapeutics for asthma. However, efficient delivery of siRNAs remains a key obstacle to their successful application. A targeted intracellular delivery approach for siRNA to specific cell types would be highly desirable. We used packaging RNA (pRNA), a component of the bacteriophage phi29-packaging motor, to deliver STAT5b siRNA to asthmatic spleen lymphocytes. This pRNA was able to spontaneously carry siRNA/STAT5b and aptamer/CD4, which is a ligand to CD4 molecule. Based on RT-PCR data, the pRNA dimer effectively inhibited STAT5b gene mRNA expression of asthmatic spleen lymphocytes, without the need for additional transfections. We conclude that the pRNA dimer carrying both siRNA and aptamer can deliver functional siRNA to cells; possibly, the aptamer acts as a ligand to interact with specific receptors. The pRNAs were evaluated with a CCK-8 kit and were found to have little cytotoxicity. We conclude that ©FUNPEC-RP www.funpecrp.com.br Genetics and Molecular Research 11 (3): 3236-3245 (2012) pRNA as a novel nanovehicle for therapy in asthma 3237pRNA as a novel nanovehicle for RNA worth further study.

show abstract

Gene Therapy for Allergic Airway Diseases

Cited by 25 publications

References 46 publications

Construction of a lentiviral vector encoding heme oxygenase 1 and its introduction into mouse adipose tissue-derived stem cells

Construction of a lentiviral vector encoding heme oxygenase 1 and its introduction into mouse adipose tissue-derived stem cells

Nanocomplexes for gene therapy of respiratory diseases: Targeting and overcoming the mucus barrier

Bottom-up assembly of RNA nanoparticles containing phi29 motor pRNA to silence the asthma STAT5b gene

Contact Info

Product

Resources

About